REGENXBIOs Breakthrough in Duchenne Muscular Dystrophy Treatment
REGENXBIO Breakthrough in Duchenne Muscular Dystrophy Treatment REGENXBIO, a leader in gene therapy innovations, has achieved remarkable progress in the ...
© 2024 Stocks Today
Tag: RGNX
Analysts Upbeat on Regenxbios Future Prospects
Regenxbio's shares have surged following an upgrade from RBC Capital, who raised their price target to $35 and upgraded the ...
Wedbush Analyst Maintains Neutral Rating on Regenxbio with 21 Price Target
Wedbush analyst Andreas Argyrides has once again assessed Regenxbio (NASDAQ:RGNX) with a Neutral rating and upholds a $21 price target. ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Unlocking Potential: How Recent Acquisitions in the Battery Technology Sector Are Reshaping the Energy Landscape